To accelerate global cancer research through data sharing, has become an international consensus. The first national China gene pool has been officially put into operation in September this year, the United States has enabled the anti-cancer “Moon” the first large-scale open database, the United States, Britain and Holland Research Institute also co founded the new cancer cell culture model library.

Beijing Cancer Hospital and Beijing Cancer Hospital Dean Ji Jiafu said, is the foreign cancer center and drug development enterprise cooperation, to obtain genetic data for each patient, build accurate medical database, according to the different types of genes required for clinical trials, clinical trials to target patients.

Ji Jiafu said, the focus of China’s various types of cancer research groups, and conducive to further expand the data acquisition. If you can break the top between research institutions and hospitals to participate in clinical trials of domestic barrier, more patients will eventually benefit more cancer patients.

Advanced technology + data = Chinese advantage

Experts said that the genomic mass of information, can be used to determine the causes of cancer, the development status and possible trends, and based on the gene sequence and function of the known drug design. As an important force in China’s genomics research, continue to play an important role in the international arena.

Academician of the Academy of engineering, China China Academy of Medical Sciences, Cao Xuetao said the Chinese government in recent years more and more attention of medical innovation, especially the basic science research and clinical application, believe on the frontiers of knowledge and the introduction of China’s population, can complete the corresponding clinical trials to solve medical problems faster and more.

Yan Hai said, pangen as a deep research in the field of cancer genomics and clinical transformation, is to use gene technology platform, and clinical and scientific experts together, for our cancer patients, cancer high-risk population and healthy population, genetic risk assessment of cancer molecular diagnosis and treatment scheme of reliable and professional.